EQS-News: Atriva Therapeutics GmbH / Key word(s): Letter of Intent Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology 18.09.2023 / 15:05 CET/CEST The issuer is solely responsible for the content of this announcement. Atriva Therapeut.
NurExone Announces Completion of Securites for Debt Settlement streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Calgary, Alberta (Newsfile Corp. - December 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company
Calgary, Alberta (Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing
CALGARY, AB / ACCESSWIRE / November 24, 2022 / Ivrnet Inc. (TSXV:IVI) ("Ivrnet" or the "Company") announces that it has filed its condensed interim consolidated financial statements for the three and nine-months